Eculizumab in kidney diseases
The C5 inhibitor monoclonal antibody, eculizumab, has been approved for the treatment of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); however, the efficacy and safety of this drug in treating other complement-related renal diseases has not yet been elucida...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Livro |
| Publicado em: |
Society of Diabetic Nephropathy Prevention,
2024-01-01T00:00:00Z.
|
| Assuntos: | |
| Acesso em linha: | Connect to this object online. |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
Internet
Connect to this object online.3rd Floor Main Library
| Área/Cota: |
A1234.567 |
|---|---|
| Cód. Barras: 1 | Disponível |